Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort – Bio Tech Winners


Reader Interactions

This site uses Akismet to reduce spam. Learn how your comment data is processed.



Source link

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *